Expansion Opportunity Alcami (formerly AAIPharma/Cambridge Major) has recent facility expansions and a footprint in Philadelphia with a 40,000-square-foot expansion. This suggests potential for process development, analytical testing, or manufacturing scale-up partnerships as customer programs move from development to commercial production.

Integrated Capabilities The company offers drug product, lab services, and API development/manufacturing capabilities. This integrated offering creates cross-sell opportunities to customers seeking a single partner for formulation, analytical testing, and API supply across development stages.

Mid market Strength With revenue in the $250M–$500M range and a workforce of 201–500, Alcami sits in the mid-market segment, making it a compelling cadence target for mid-sized pharma and contract development/manufacturing organizations seeking reliable, scalable manufacturing partners.

Growth Readiness Recent location expansion plus a reported funding round indicate growth momentum. This can be used to position for expansion-oriented programs, technology upgrades, or capacity-adding collaborations with clients planning rapid scale or entering new markets.

Competitive Positioning In a field with large CRO/CDMO peers, Alcami’s combination of legacy capabilities and growth projects can be leveraged to approach companies comparing big-operator throughput with specialized, flexible mid-size partners for faster onboarding and customized development timelines.